The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations

Clinical Pharmacokinetics

Volumn 32, Issue 5, 1997, Pages 357-367

  Jones, Terry E ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DILTIAZEM; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; VERAPAMIL;

CARDIOVASCULAR DISEASE; CITRUS FRUIT; COST CONTROL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG METABOLISM; DRUG MONITORING; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE COST; HUMAN; HYPOTENSION; IMPOTENCE; LIVER TOXICITY; MEDICAL ETHICS; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0031006546     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732050-00002     Document Type: Review

References (100)

1. Lindholm A. Therapeutic monitoring of cyclosporin: an update. Eur J Clin Pharmacol 1991; 41: 273-83
2. Friman S, Backman L. A new micromulsion formulation of cyclosporin: pharmacokinetic and clinical features. Clin Pharmacokinet 1996; 3: 181-93
3. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992; 33: 39-43
4. Jacqz-Agrain E, Montes C, Brun P, et al. Cyclosporin pharmacokinetics in nephrotic and kidney transplanted children. Eur J Clin Pharmacol 1994; 47: 61-5
5. Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al. Cyclosporin bioavailability in liver disease. DICP 1985; 19: 451
6. Levy G, Rochon J, Freeman D, et al. Cyclosporine neoral in liver transplant recipients. Transplant Proc 1994; 5: 2949-52
7. Lindholm A, Henricsson S, Dahlqvist R. The effect of food and bile acid administration on the relative bioavailabilty of cyclosporin. Br J Clin Pharmacol 1990; 29: 541-8
8. Tan KKC, Trull AK, Uttridge JA, et al. Relative bioavailabilty of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis. Eur J Clin Pharmacol 1995; 48: 285-9
9. Whitington PF, Edmond JC, Whitington SH, et al. Small bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990; 322: 733-8
10. Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992; 21 (3): 511-26
11. Kronbach T, Fischer V, Meyer UA. Cyclosporin metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporin-metabolizing enzyme explains interactions of cyclosporin with other drugs. Clin Pharmacol Ther 1988; 43 (6): 630-5
12. Combalbert J, Fabre I, Fabre G, et al. Purification and identification of the rifampicin-inducible liver cytochrome P-450 (cyclosporin A oxidase) as a product of the P450IIIA gene subfamily. Drug Metab Dispos 1989; 17 (2): 197-207
13. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab Dispos 1994; 22 (6): 947-55
14. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040
15. Kolars JC, Awni WM, Merion RM, et al. First pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-90
16. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492-7
17. Dieperink H, Moller J. Ketoconazole and cyclosporin. Lancet 1982; II: 1217
18. Wadhwa NK, Schroeder TJ, Pesce AJ, et al. Cyclosporine drug interactions: a review. Ther Drug Monit 1987; 9: 399-406
19. Bailey DG, Malcolm JO, Spence DJ. Grapefruit juice and drugs: how significant is the interaction. Clin Pharmacokinet 1994; 26 (2): 91-8
20. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485-91
21. Ducharme MP, Provenzano R, Dehoorne-Smith M, et al. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993; 36: 457-9
22. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345: 955-6
23. Hollander AAMJ, van Rooij J, Lentjes EGWM, et al. The effect of grapefruit juice on cyclosporin and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995; 57 (3): 318-24
24. Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59 (4): 383-8
25. Kupferschmidt HHT, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20-8
26. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter prinicipal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993; 35: 431-6
27. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; I: 268-9
28. Johnston A, Holt DW. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 346: 122-3
29. Hollander AA, van der Woude FJ, Cohen AF. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 346: 123
30. Tortorice KL, Heim-Duthoy KL, Awni WM, et al. The effects of calcium channel blockers on cyclosporin and its metabolites in renal transplant recipients. Ther Drug Monit 1990; 12 (4): 321-8
31. Sketris IS, Methot ME, Nicol D, et al. Effect of calcium-channel blockers on cyclosporin clearance and use in renal transplant patients. Ann Pharmacother 1994; 28: 1227-31
32. Wagner K, Philipp Th, Heinemeyer G, et al. Interaction of cyclosporin and calcium antagonists. Transplant Proc 1989; 21 (1): 1453-56
33. Wagner K, Henkel M, Heinemeyer G, et al. Interaction of calcium blockers and cyclosporine. Transplant Proc 1988; 20 (2) Suppl. 2: 561-8
34. Kessler M, Netter P, Renoult E, et al. Influence of nicardipine on renal function and plasma cyclosporin in renal transplant patients. Eur J Clin Pharmacol 1989; 36: 637-8
35. Guan D, Wang R, Lu J, et al. Effects of nicardipine on blood cyclosporine levels in renal transplant patients. Transplant Proc 1996; 28 (3): 1311-2
36. Bourbigot B, Guiserix J, Airiau J, et al. Nicardipine increases cyclosporin blood levels. Lancet 1986; I: 1447
37. Wagner K, Neumayer HH. Prevention of delayed graft function in cadaver kidney transplants by diltiazem. Lancet 1985; II: 1355-6
38. Pochet JM, Pirson Y. Cyclosporin-diltiazem interaction. Lancet 1986; I: 979
39. Chrysostomou A, Walker RG, Russ GR, et al. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993; 55 (2): 300-4
40. Oppenheimer F, Alcaraz A, Manulich M, et al. Influence of the calcium blocker diltiazem on the prevention of acute renal failure after renal transplantation. Transplant Proc 1992; 24 (1): 50-1
41. Wagner K, Albrecht S, Neumayer HH. Prevention of posttransplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomised study. Am J Nephrol 1987; 7: 287-91
42. Carozzi S, Nasini MG, Pietrucci A, et al. Immunosuppressive effects of different calcium channel blockers in human kidney allografts. Transplant Proc 1995; 27 (1): 1054-7
43. Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients. N Engl J Med 1993; 328: 164-70
44. Shennib H, Auger J. Diltiazem improves cyclosporin dosage in cystic fibrosis lung transplant recipients. J Heart Lung Transplant 119; 13 (2): 292-6
45. Valentine H, Keogh A, McIntosh N, et al. Cost containment: Coadministration of diltiazem with cyclosporine after heart transplantation. J Heart Lung Transplant 1992; 11: 1-8
46. Neumayer HH, Wagner K. Diltiazem and economic use of cyclosporin. Lancet 1986; II: 523
47. Brockmoller J, Neumayer HH, Wagner K, et al. Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 1990; 38: 237-42
48. Patton PR, Brunson ME, Pfaff WW, et al. A preliminary report of diltiazem and ketoconazole: their cyclosporin-sparing effect and impact on transplant outcome. Transplantation 1994; 57 (6): 889-92
49. Jones TE, Morris RG. Diltiazem does not always increase blood cyclosporin concentration. Br J Clin Pharmacol 1996; 42: 642-4
50. Henricsson S, Lindholm A. Inhibition of cyclosporine metabolism by other drugs in vitro. Transplant Proc 1988; 20 (2) Suppl. 2: 569-71
51. Lindholm A, Henricsson S. Verapamil inhibits cyclosporin metabolism. Lancet 1987; I: 1262-3
52. Robson RA, Fraenkel M, Barratt LJ, et al. Cyclosporin-verapamil interaction. Br J Clin Pharmacol 1988; 25: 402-3
53. Maggio TG, Bartels DW. Increased cyclosporin blood concentrations due to verapamil administration. DICP 1988; 22: 705-7
54. Dawidson I, Ar'Rajab A, Dickerman R, et al. Perioperative albumin and verapamil improve early outcome after cadaver renal transplantation. Transplant Proc 1994; 26 (6): 3100-1
55. Ferguson RM, Sutherland DR, Simmons RL, et al. Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet 1482; II: 882-3
56. First MR, Schroeder TJ, Weiskittel P, et al. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet 1989; II: 1198-201
57. First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 1991; 51: 365-70
58. First MR, Schroeder TJ, Michela A, et al. Cyclosporine-ketoconazole interaction: long term follow up and preliminary results of a randomized trial. Transplantation 1993; 55: 1000-4
59. Odocha O, Kelly B, Trimble S, et al. Cost-containment strategies in transplantation: the utility of cyclosporine-ketoconazole combination therapy. Transplant Proc 1996; 28 (2): 907-
60. Sobh M, El-Agroudy A, Moustafa F, et al. Coadministration of ketoconazole to cyclosporin treated kidney transplant recipients: a prospective randomised study Am J Nephrol 1995; 15: 493-9
61. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailabilty of cyclosporine. Clin Pharmacol Ther 1995; 58: 15-9
62. Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333: 628-33
63. Frey FJ. Concomitant cyclosporin and ketoconazole. Lancet 1990; I: 109-10
64. Jones TE. Survey of cyclosporin sparing agent use in Australasian transplant centres. Aust NZ J Med 1996; 26: 772-6
65. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991; 32: 624-6
66. Kwan JTC, Foxall PJD, Davidson DGC, et al. Interaction of cyclosporin and itraconazole. Lancet 1987; II: 282
67. Gupta SK, Manfro RC, Tomlanovich SJ, et al. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 1990; 30: 643-53
68. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, et al. The effect of food on cyclosporine absorption. Transplantation 1985; 40: 174-6
69. Keogh A, Day R, Critchley L, et al. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc 1988; 20: 27-30
70. Puff MR, Carey WD. The effect of cimetidine on cyclosporine A levels in liver transplant recipients: a preliminary report. Am J Gastroenterol 1992; 87: 287-91
71. Adu D, Michael J, McMaster P. Conversion from cyclosporin to azathioprine/prednisolone. Lancet 1985; I: 392
72. Veitch PS, Horsburgh T, Parvin S, et al. Elective conversion from cyclosporin-A (CyA) to azathioprine (Aza) at 3 months. Transplant Proc 1985; 17: 2044
73. Hall BM, Tiller DJ, Hardie I, et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporine, short term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 1988; 318: 1499-507
74. Hollander AAMJ, van Sasse JLCM, Kootte AMM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610-14
75. Jones TE, Morris RG. Survey of cyclosporin therapeutic ranges, assay methodology and use of 'sparing agents' in Australasian transplant centres. Ther Drug Monit. In press
76. Curtis JJ, Dubovsky E, Whelchel JD, et al. Cyclosporin in therapeutic doses increases renal allograft resistance. Lancet 1986; II: 477-9
77. Odds PO, Webster CE. Effects of azole antifungals in vitro on host parasite interactions relevant to candida infections. J Antimicrob Chemother 1988; 22: 173-81
78. Senior DS, Shaw JT. In vitro effect of fluconazole (UK-19858) and ketoconazole on mouse lymphocyte proliferation and on candida blastospore destruction by human polymorphonuclear leukocytes. Int J Immunopharmacol 1988; 10: 169-73
79. Aabo K, De Coster R. Hypertension during high dose ketoconazole treatment: a probable mineralocorticosteroid effect. Lancet 1987; II: 637-8
80. Lewis JH, Zimmerman HJ, Benson GD, et al. Hepatic injury associated with ketoconazole therapy. Gastroenterology 1984; 86: 503-13
81. Tester-Dalderup CBM. Antifungal drugs In: Dukes MNG, editor. Meyler's side effects of drugs. Amsterdam: Elsevier, 1992: 677-8
82. Kunzendorf U, Brockmoller J, Jochimsen F, et al. Cyclosporin metabolites and central nervous system toxicity. Lancet 1988; I: 1223
83. Kunzendorf U, Brockmoller J, Jochimsen F, et al. Immunosuppressive properties of cyclosporin metabolites. Lancet 1989; I: 734-5
84. Freed BM, Rosano TG, Lempert N. In vitro immunosuppressive properties of cyclosporine metabolites. Transplantation 1987; 43 (1): 123-7
85. Kunzendorf U, Brockmoller J, Jochimsen F, et al. Neurotoxicity caused by a high cyclosporine metabolite level. Transplantation 1989; 48 (3): 531-2
86. Lucey MR, Kolars JC, Merion RM, et al. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 1990; 335: 11-5
87. Didlake RH, Dreyfus K, Kerman RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporine treated renal transplants. Transplant Proc 1988; 20 (3 Suppl. 3): 63-9
88. Kiley DJ, Lam CS, Pollak R. A study of treatment compliance following kidney transplantation. Transplantation 1993; 55 (1): 51-6
89. Schweizer RT, Rovelli M, Palmeri D, et al. Noncompliance in organ transplant recipients. Transplantation 1990; 49: 374-7
90. Jones TE, Morris RG, Mathew TH. Formulation of diltiazem affects cyclosporin-sparing activity. Eur J Clin Pharmacol. In press
91. Cooke CE. Nontherapeutic cyclosporin levels: sustained-Release diltiazem products are not the same. Transplantation 1994; 57 (11): 1687
92. Gupta SK, Bakran A, Johnson RWG, et al. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989; 27: 475-81
93. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 1989; 45: 366-72
94. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-90
95. Kivisto KT, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 1994; 27: 1-5
96. Product information. In: Tatro DS, editor. Drug interaction facts. Facts and comparison. St. Louis: Jansenn Pharmaceutics, 1995: 191
97. Karlix JL, Cheng MA, Brunson ME, et al. Decreased cyclosporine concentrations with the addition of an H2 receptor antagonist in a patient on ketoconazole. Transplantation 1993; 56 (6): 1554-5
98. Niese D. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. Transplant Proc 119; 27 (2): 1849-56
99. Prograf [Prescription products]. Pharm J 1994; 253: 587
100. Mycophenolate mofetil: a new immunosuppressant for organ transplantation. Med Lett Drugs Ther 1995; 37: 84-6